DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that it introduced a new gamma detection probe at the recent American College of Surgeons (ACS) 93rd Annual Clinical Congress meeting in San Francisco. The new probe is based on Bluetooth® wireless technology and is intended for use in laparoscopic procedures to communicate gamma radiation counts to the Company’s neoprobe® GDS or neo2000 gamma detection control units. The neoprobe GDS control unit contains internal circuitry that enables it to communicate with Neoprobe’s family of wireless probes without the necessity of an external adapter. However, the new wireless laparoscopic probe is designed to be compatible with all previous models of the Company’s neo2000 system (Models 2000, 2100 and 2200). Neoprobe’s wireless gamma detection products eliminate cumbersome cables that can unnecessarily complicate the surgical field. Neoprobe’s line of gamma detection systems are widely used by cancer surgeons in a procedure called Sentinel Lymph Node Biopsy (SLNB) or Intraoperative Lymphatic Mapping (ILM).
